Project Grant R03CA308545
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Cancer Institute awarded the University of California, San Diego $469,972 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a three-year study examining how state health insurance benefit mandates for fertility preservation impact affordability and utilization of fertility preservation services among children, adolescents, and young adults newly diagnosed with cancer. The study will characterize outcomes of fertility preservation...
- The National Cancer Institute awarded The Washington University $882,444 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to test clarified imaging reports designed to reduce anxiety, fear of cancer recurrence, and improve understanding of follow-up care needs among adult survivors of pediatric brain cancer. The research comprises three aims. Aim 1 will explore through interviews how adult survivors of pediatric brain cancer and their care teams prefer...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...
- The National Cancer Institute awarded Children's Hospital Los Angeles $8.473 million on September 10, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a patient navigation intervention designed to improve transition success among multiply disadvantaged young adult survivors of childhood cancer. The intervention addresses a documented gap in survivorship care: while childhood cancer survival rates exceed 85 percent, treatment-related late effects...
- This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...
- The National Cancer Institute awarded the University of Louisville $654,474 on August 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to implement and test a stepped oncology financial and legal navigation (OFLN) intervention for adolescent and young adult cancer patients experiencing financial toxicity. The project will conduct a randomized hybrid effectiveness-implementation trial comparing stepped OFLN—which risk-stratifies patients into low-intensity web-based...
- The National Cancer Institute awarded The Leland Stanford Junior University $258,945 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and pilot test Roadmap to Parenthood, an evidence-based digital decision aid and planning tool for family building after cancer. Roadmap was originally developed for women who completed gonadotoxic cancer treatment and demonstrated improvements in knowledge, self-efficacy, decisional conflict, and patient-provider...
- The National Cancer Institute awarded Vanderbilt University Medical Center $518,470 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize links between fertility and energy balance among young patients after early-onset colorectal cancer diagnosis. The award funds prospective collection of physical activity, sedentary behavior, and reproductive health questionnaires, plus one-week accelerometry-assessed physical activity data from colorectal cancer...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded The Washington University $160,093 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate perceptions and informational needs regarding prostate cancer screening among screening-eligible men, with particular attention to racial disparities. The research addresses how men perceive the harms and benefits of prostate-specific antigen (PSA)-based screening, especially in the context of risk-stratified screening...